10,815 Shares in Natera, Inc. $NTRA Acquired by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 10,815 shares of the medical research company’s stock, valued at approximately $2,936,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Coatue Management LLC boosted its holdings in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the last quarter. Norges Bank purchased a new stake in Natera in the fourth quarter valued at $372,398,000. JPMorgan Chase & Co. lifted its position in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Natera by 39.0% in the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after acquiring an additional 673,315 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research reports. Barclays reaffirmed an “overweight” rating and set a $340.00 price objective on shares of Natera in a report on Friday. William Blair began coverage on Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. BTIG Research raised their price target on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Morgan Stanley lifted their price target on Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $299.65.

Natera Stock Performance

Shares of Natera stock opened at $322.10 on Friday. The company has a market capitalization of $46.13 billion, a P/E ratio of -236.84 and a beta of 1.51. Natera, Inc. has a 1 year low of $149.38 and a 1 year high of $323.01. The company’s fifty day moving average is $254.03 and its two-hundred day moving average is $223.79.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.82%. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period in the prior year, the company earned ($0.74) earnings per share. The business’s revenue was up 37.7% compared to the same quarter last year. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director directly owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 181,045 shares of company stock worth $41,330,968 over the last three months. 5.05% of the stock is currently owned by company insiders.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.